Actively Recruiting

Phase 3
Age: 18Years - 44Years
FEMALE
NCT06746129

Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos

Led by Beth Israel Deaconess Medical Center · Updated on 2026-04-02

1126

Participants Needed

1

Research Sites

302 weeks

Total Duration

On this page

Sponsors

B

Beth Israel Deaconess Medical Center

Lead Sponsor

B

Brigham and Women's Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Infertility affects more than 6 million women the United States and is a major life event that results in a wide range of socio-cultural, emotional, physical and financial problems. The most successful treatment for infertility, in-vitro fertilization (IVF), fertilizes a woman's eggs with her partner's sperm in a culture dish and transfers the resulting embryos into the uterus. Most of the time, prior to being transferred, embryos are grown in the dish for 5-7 days after which some of them reach an advanced stage (blastocyst stage). This has several advantages such as a lower chance of a multiple pregnancies (twins, triplets etc.) after transfer and fewer transfer procedures. However, it is possible that embryos would survive better if transferred into the uterus at the 8-cell stage after growing them for only 3 days. Thus, when patients only have a small number of embryos they and their physicians face the difficult choice when to transfer because there are currently no studies available to guide this decision. This randomized controlled trial is comparing pregnancy outcomes and patient satisfaction of poor prognosis patients with 5 or fewer embryos undergoing either transfer of an advanced (blastocyst) or an 8-cell embryo. This study will provide the data for the development of guidelines for IVF providers to make evidence-based decisions when to transfer embryos in poor prognosis IVF patients, reduce patients' anxiety regarding cycle cancellation and improve patient counseling, which will increase patients' ability to participate in the development of their treatment plan.

CONDITIONS

Official Title

Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos

Who Can Participate

Age: 18Years - 44Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Undergoing autologous IVF cycle
  • Having 5 or fewer zygotes on day 1 of embryo development
  • Receiving fresh embryo transfer
Not Eligible

You will not qualify if you...

  • Planned preimplantation genetic testing (PGT) of all embryos
  • More than 2 previous IVF cycles
  • History of recurrent pregnancy loss (3 or more losses)
  • Body mass index (BMI) greater than 40
  • Presence of uterine factor infertility
  • Planned use of a gestational carrier
  • Endometrial lining thinner than 6mm on the day of trigger
  • Use of Lupron-only trigger or elevated progesterone (1.5 ng/ml or higher) in the fresh cycle
  • Fertilization delayed more than 18 hours
  • Use of rescue intracytoplasmic sperm injection after failed fertilization
  • Use of non-ejaculated sperm (testicular sperm extraction)
  • Number of embryos transferred outside American Society of Reproductive Medicine guidelines
  • Cycle converted to all embryos being frozen

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Boston IVF

Boston, Massachusetts, United States, 02451

Actively Recruiting

Loading map...

Research Team

B

Beatrice Duvert

CONTACT

W

Werner Neuhausser, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here